Abstract 1147: microRNA expression profiling in cisplatin resistant human non-small cell lung cancer cell lines

Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL Cisplatin combination chemotherapy is one of the important treatments for many cancers including lung cancer. Despite impressive initial clinical responses, the majority of patients eventually develop some degree of resistance to cisplatin-based therapy. To understand the clinically relevant mechanisms of resistance, many studies have been aimed at clarifying the biochemical/molecular alterations of cisplatin-resistant cells. However, cellular resistance mechanisms of cisplatin are still unclear. MicroRNA (miRNA) is small noncoding RNA that function to control gene expression. These small RNAs have been shown to contribute to the control of cell growth, differentiation and apoptosis, important features related to cancer development progression and sensitivity of chemotherapy. However, the interaction between the development of cisplatin resistance and miRNA has not been previously explored. In this study we utilized a miRNA array to compare the differentially expressed miRNAs in cisplatin-resistant cell lines, PC-9/CPr and PC-14/CPr and their parental cell lines, PC-9 and PC-14. We verified that miR-7, miR-106 and miR-181 were up-regulated in cisplatin-resistant non-small cell lung cancer cells by means of real-time PCR and discusses the potential of these miRNAs as biomarkers for cisplatin sensitivity in combination chemotherapy. We further investigated the role and mechanisms of miR-181 in cisplatin resistance. We found that specific miR-181 precursor (Pre-miR-181) transfection significantly acquired cisplatin resistance. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1147. doi:10.1158/1538-7445.AM2011-1147